文献速递血栓与止血

评估实体瘤门诊患者预防性使用肝素:系统评价与个体参与者数据Meta分析

Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis.
PubMed 文献 · Lancet Haematol · 2020-01-01

该系统评价与个体参与者数据Meta分析纳入14项随机对照试验的8278例实体瘤门诊患者,比较低分子量肝素与安慰剂或标准治疗。低分子量肝素降低静脉血栓栓塞风险(调整RR 0.58,95%CI 0.47-0.71),不增加大出血风险(调整RR 1.27,95%CI 0.92-1.74),但未改善生存(1年死亡率调整RR 0.99,95%CI 0.93-1.06)。

要点

  • 低分子量肝素降低实体瘤门诊患者静脉血栓栓塞风险,调整RR 0.58(95%CI 0.47-0.71)。
  • 低分子量肝素不增加大出血风险,调整RR 1.27(95%CI 0.92-1.74),但增加小出血风险,调整RR 1.34(95%CI 1.19-1.51)。
  • 低分子量肝素未改善生存,1年死亡率调整RR 0.99(95%CI 0.93-1.06),风险比1.01(95%CI 0.96-1.07)。

核心结论

  • 与安慰剂或标准治疗相比,低分子量肝素降低实体瘤患者静脉血栓栓塞风险且不增加大出血风险,但不改善生存。

研究设计与样本

  • 系统评价与个体参与者数据Meta分析,检索MEDLINE、Embase和Cochrane图书馆从建库至2017年1月14日,并于2020年5月14日更新,无语言限制。
  • 纳入比较肠外抗凝药与安慰剂或标准治疗的随机对照试验,对象为无抗凝指征的实体瘤门诊患者。
  • 获得20项合格随机对照试验中14项的个体参与者数据,共8278例(占10431例的79%),低分子量肝素组4139例,对照组4139例。
  • 采用多变量分层模型,患者水平变量为固定效应,分类试验变量为随机效应,调整年龄、癌症类型和转移状态。
  • 研究注册于PROSPERO,CRD42013003526。

主要发现

  • 1年死亡率调整RR为0.99(95%CI 0.93-1.06),风险比为1.01(95%CI 0.96-1.07)。
  • 静脉血栓栓塞事件在低分子量肝素组为3958例可评估患者中158例(4.0%),对照组为3957例中279例(7.1%)。
  • 大出血事件在对照组为4139例中71例(1.7%),低分子量肝素组为4139例中88例(2.1%)。
  • 小出血事件在对照组为3945例可评估患者中478例(12.1%),低分子量肝素组为3937例中652例(16.6%)。
  • 调整RR:静脉血栓栓塞0.58(95%CI 0.47-0.71),大出血1.27(95%CI 0.92-1.74),小出血1.34(95%CI 1.19-1.51)。

临床怎么用

  • 原文结论为低分子量肝素降低实体瘤患者静脉血栓栓塞风险且不增加大出血风险,但不改善生存;原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Study-level meta-analyses provide high-certainty evidence that heparin reduces the risk of symptomatic venous thromboembolism for patients with cancer; however, whether the benefits and harms associated with heparin differ by cancer type is unclear. This individual participant data meta-analysis of randomised controlled trials examines the effect of heparin on survival, venous thromboembolism, and bleeding in patients with cancer in general and by type. METHODS: In this systematic review and meta-analysis we searched MEDLINE, Embase, and The Cochrane Library for randomised controlled trials comparing parenteral anticoagulants with placebo or standard care in ambulatory patients with solid tumours and no indication for anticoagulation published from the inception of each database to January 14, 2017, and updated it on May 14, 2020, without language restrictions. We calculated the effect of parenteral anticoagulant administration on all-cause mortality, venous thromboembolism occurrence, and bleeding related outcomes through multivariable hierarchical models with patient-level variables as fixed effects and a categorical trial variable as a random effect, adjusting for age, cancer type, and metastatic status. Interaction terms were tested to investigate effects in predefined subgroups. This study is registered with PROSPERO, CRD42013003526. FINDINGS: We obtained individual participant data from 14 of 20 eligible randomised controlled trials (8278 [79%] of 10 431 participants; 4139 included in the low-molecular-weight heparin group and 4139 in the control group). Meta-analysis showed an adjusted relative risk (RR) of mortality at 1 year of 0·99 (95% CI 0·93-1·06) and a hazard ratio of 1·01 (95% CI 0·96-1·07). The number of patients with venous thromboembolic events was 158 (4·0%) of 3958 with available data in the low-molecular-weight heparin group compared with 279 (7·1%) of 3957 in the control group. Major bleeding events occurred in 71 (1·7%) of 4139 patients in the control population and 88 (2·1%) in the low-molecular-weight heparin group, and minor bleeding events in 478 (12·1%) of 3945 patients with available data in the control group and 652 (16·6%) of 3937 patients in the low-molecular-weight heparin group. The adjusted RR was 0·58 (95% CI 0·47-0·71) for venous thromboembolism, 1·27 (0·92-1·74) for major bleeding, and 1·34 (1·19-1·51) for minor bleeding. Prespecified subgroup analysis of venous thromboembolism occurrence by cancer type identified the most certain benefit from heparin treatment in patients with lung cancer (RR 0·59 [95% CI 0·42-0·81]), which dominated the overall reduction in venous thromboembolism. Certainty of the evidence for the outcomes ranged from moderate to high. INTERPRETATION: Low-molecular-weight heparin reduces risk of venous thromboembolism without increasing risk of major bleeding compared with placebo or standard care in patients with solid tumours, but it does not improve survival. FUNDING: Canadian Institutes of Health Research.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Schünemann HJ, Ventresca M, Crowther M, et al. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematol. 2020. PMID: 32976752. doi:10.1016/S2352-3026(20)30293-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。